Literature DB >> 31818805

Haemodynamic phenotypes and survival in patients with systemic sclerosis: the impact of the new definition of pulmonary arterial hypertension.

Panagiota Xanthouli1,2, Suzana Jordan3, Nicklas Milde1,2, Alberto Marra4, Norbert Blank5, Benjamin Egenlauf1,2, Matthias Gorenflo6, Satenik Harutyunova1,2, Hanns-Martin Lorenz5, Christian Nagel1,2,7, Vivienne Theobald1,2, Mona Lichtblau8, Charlotte Berlier8, Silvia Ulrich8, Ekkehard Grünig1,2, Nicola Benjamin9,2, Oliver Distler3.   

Abstract

BACKGROUND: In this study, we investigated the impact of the new haemodynamic definition of pulmonary arterial hypertension (PAH) as proposed by the 6th PH World Symposium on phenotypes and survival in patients with systemic sclerosis (SSc).
METHODS: In SSc patients who were prospectively and consecutively screened for PAH including right heart catheterisation in Heidelberg or Zurich, haemodynamic and clinical variables have been reassessed according to the new PAH definition. Patients have been followed for 3.7±3.7 (median 3.4) years; Kaplan-Meier survival analysis was performed. Patients with significant lung or left heart disease were excluded from comparative analyses.
RESULTS: The final dataset included 284 SSc patients, 146 patients (49.2%) had mean pulmonary arterial pressure (mPAP) ≤20 mm Hg, 19.3% had mPAP 21-24 mm Hg and 29.4% had mPAP ≥25 mm Hg. In the group of mildly elevated mPAP, only four patients (1.4% of the whole SSc cohort) had pulmonary vascular resistance (PVR) values ≥3 Wood Units (WU) and could be reclassified as manifest SSc-APAH. Twenty-eight (9.8%) patients with mPAP of 21-24 mm Hg and PVR ≥2 WU already presented with early pulmonary vascular disease with decreased 6 min walking distance (6MWD) (p<0.001), TAPSE (p=0.004) and pulmonary arterial compliance (p<0.001). A PVR ≥2 WU was associated with reduced long-term survival (p=0.002). PVR and 6MWD were independent prognostic predictors in multivariate analysis.
CONCLUSION: The data of this study show that a PVR threshold ≥3 WU is too high to enable an early diagnosis of PAH. A PVR threshold ≥2 WU was already associated with pulmonary vascular disease, significantly reduced survival and would be more appropriate in SSc patients with mild PAH. © Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  outcomes research; systemic sclerosis; treatment

Year:  2019        PMID: 31818805     DOI: 10.1136/annrheumdis-2019-216476

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Impact of the revised hemodynamic definition on the diagnosis of precapillary pulmonary hypertension: a retrospective single-center study in China.

Authors:  Qi Jin; Yi Zhang; Zhihui Zhao; Qing Zhao; Xue Yu; Lu Yan; Xin Li; Anqi Duan; Chenhong An; Xiuping Ma; Changming Xiong; Qin Luo; Zhihong Liu
Journal:  Cardiovasc Diagn Ther       Date:  2021-10

2.  Cross-cultural validation of the Chinese version of the EmPHasis-10 questionnaire in connective tissue disease patients with pulmonary arterial hypertension and its relationship with risk stratification.

Authors:  Yue Shi; Xingbei Dong; Xiaoyun Hu; Li Weng; Yongtai Liu; Jinzhi Lai; Zhuang Tian; Jiuliang Zhao; Mengtao Li; Jinmin Peng; Qian Wang; Xiaofeng Zeng
Journal:  BMC Pulm Med       Date:  2022-07-05       Impact factor: 3.320

Review 3.  Cardiopulmonary Hemodynamics in Pulmonary Hypertension and Heart Failure: JACC Review Topic of the Week.

Authors:  Bradley A Maron; Gabor Kovacs; Anjali Vaidya; Deepak L Bhatt; Rick A Nishimura; Susanna Mak; Marco Guazzi; Ryan J Tedford
Journal:  J Am Coll Cardiol       Date:  2020-12-01       Impact factor: 24.094

4.  Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances.

Authors:  Bradley A Maron; Steven H Abman; C Greg Elliott; Robert P Frantz; Rachel K Hopper; Evelyn M Horn; Mark R Nicolls; Oksana A Shlobin; Sanjiv J Shah; Gabor Kovacs; Horst Olschewski; Erika B Rosenzweig
Journal:  Am J Respir Crit Care Med       Date:  2021-06-15       Impact factor: 30.528

5.  Influence of Upright Versus Supine Position on Resting and Exercise Hemodynamics in Patients Assessed for Pulmonary Hypertension.

Authors:  Charlotte Berlier; Stéphanie Saxer; Mona Lichtblau; Simon R Schneider; Esther I Schwarz; Michael Furian; Konrad E Bloch; Arcangelo F Carta; Silvia Ulrich
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

6.  Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Dirk M Wuttge; Anting L Carlsen; Gabriel Teku; Marie Wildt; Göran Rådegran; Mauno Vihinen; Niels H H Heegaard; Roger Hesselstrand
Journal:  Rheumatology (Oxford)       Date:  2021-12-24       Impact factor: 7.580

7.  Serum markers of cardiac complications in a systemic sclerosis cohort.

Authors:  Anders H Tennøe; Klaus Murbræch; Henriette Didriksen; Thor Ueland; Vyacheslav Palchevskiy; Stephen S Weigt; Håvard Fretheim; Øyvind Midtvedt; Torhild Garen; Cathrine Brunborg; Pål Aukrust; Øyvind Molberg; John A Belperio; Anna-Maria Hoffmann-Vold
Journal:  Sci Rep       Date:  2022-03-18       Impact factor: 4.379

8.  Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study.

Authors:  Bradley A Maron; Evan L Brittain; Edward Hess; Stephen W Waldo; Anna E Barón; Shi Huang; Ronald H Goldstein; Tufik Assad; Bradley M Wertheim; George A Alba; Jane A Leopold; Horst Olschewski; Nazzareno Galiè; Gerald Simonneau; Gabor Kovacs; Ryan J Tedford; Marc Humbert; Gaurav Choudhary
Journal:  Lancet Respir Med       Date:  2020-07-27       Impact factor: 30.700

Review 9.  Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis.

Authors:  Saja Almaaitah; Kristin B Highland; Adriano R Tonelli
Journal:  Integr Blood Press Control       Date:  2020-03-23

10.  Characteristics of patients meeting the new definition of pre-capillary pulmonary hypertension (Nice 2018) in a single Japanese pulmonary hypertension center.

Authors:  Keiko Yamamoto; Nobuhiro Tanabe; Yukiko Takahashi; Akira Naito; Ayumi Sekine; Rika Suda; Takayuki Jujo Sanada; Toshihiko Sugiura; Ayako Shigeta; Seiichiro Sakao; Koichiro Tatsumi
Journal:  BMC Pulm Med       Date:  2021-08-09       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.